MX2009013829A - Composiciones terapeuticas y su uso. - Google Patents

Composiciones terapeuticas y su uso.

Info

Publication number
MX2009013829A
MX2009013829A MX2009013829A MX2009013829A MX2009013829A MX 2009013829 A MX2009013829 A MX 2009013829A MX 2009013829 A MX2009013829 A MX 2009013829A MX 2009013829 A MX2009013829 A MX 2009013829A MX 2009013829 A MX2009013829 A MX 2009013829A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
therapeutic compositions
compositions
atazanavir
Prior art date
Application number
MX2009013829A
Other languages
English (en)
Inventor
Brian P Kearney
Anita A Mathias
Srinivasan Ramanathan
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2009013829A publication Critical patent/MX2009013829A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención incluye métodos, composiciones y estuches útiles para tratar una infección viral mediante la coadministración de ácido 6-(3-cloro-2-fluorobencil)-1-[(2S)-1-hidroxi-3-metilbutan-2- il]-7-metoxi-4-oxo-1 ,4-dihidroquinolin-3-carboxílíco o una sal de él aceptable farmacéuticamente con atazanavir o con una sal de él aceptable farmacéuticamente, y opcionalmente con un compuesto que inhibe al citocromo P-450, o con una sal de él aceptable farmacéuticamente.
MX2009013829A 2007-06-29 2008-06-26 Composiciones terapeuticas y su uso. MX2009013829A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94730607P 2007-06-29 2007-06-29
US4092008P 2008-03-31 2008-03-31
PCT/US2008/068339 WO2009006199A1 (en) 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof

Publications (1)

Publication Number Publication Date
MX2009013829A true MX2009013829A (es) 2010-03-10

Family

ID=39831893

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013829A MX2009013829A (es) 2007-06-29 2008-06-26 Composiciones terapeuticas y su uso.

Country Status (19)

Country Link
US (4) US20090093467A1 (es)
EP (1) EP2167088A1 (es)
JP (3) JP5547066B2 (es)
KR (1) KR20100040892A (es)
CN (2) CN101686972B (es)
AP (1) AP2965A (es)
AR (1) AR067183A1 (es)
AU (1) AU2008270630B2 (es)
BR (1) BRPI0813000A2 (es)
CA (1) CA2692101A1 (es)
CO (1) CO6251237A2 (es)
EA (1) EA200971093A1 (es)
EC (1) ECSP109897A (es)
IL (1) IL202744A0 (es)
MX (1) MX2009013829A (es)
NZ (1) NZ582086A (es)
SG (1) SG182229A1 (es)
TW (1) TW200914011A (es)
WO (1) WO2009006199A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170796A1 (en) * 2005-12-30 2011-05-30 Gilead Sciences Inc Us Methods for improving the pharmacokinetics of hiv integrase inhibitors
TWI411613B (zh) 2006-07-07 2013-10-11 Gilead Sciences Inc 用於改善被細胞色素p450單氧合酶所代謝之治療劑的藥物動力性質之調節劑
BRPI0716752A2 (pt) 2006-09-12 2013-09-17 Gilead Sciences Inc processo e intermediÁrios para preparo de inibidores de intergrase
MX2009008935A (es) * 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
KR20100028656A (ko) * 2007-06-29 2010-03-12 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
AR067183A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Composiciones terapeuticas y metodos, usos y equipos
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
WO2011127244A2 (en) * 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
US20130274254A1 (en) * 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
EP2785184B1 (en) 2011-11-30 2020-06-10 Emory University Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
AU2013296289B2 (en) 2012-08-03 2017-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CA3012242C (en) 2012-12-21 2021-11-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
JP6411491B2 (ja) 2013-07-12 2018-10-24 ギリアード サイエンシス インコーポレーテッド 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用
NO2865735T3 (es) 2013-07-12 2018-07-21
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (es) 2014-06-20 2018-06-23
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2016244035B2 (en) 2015-04-02 2018-11-01 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3706762A4 (en) 2017-12-07 2021-09-01 Emory University N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6544540B2 (en) * 1998-07-29 2003-04-08 Syngenta Limited Base-triggered release microcapsules
CZ2004764A3 (cs) * 2002-11-20 2005-02-16 Japan Tobacco Inc 4-Oxochinolinová sloučenina a její použití jako inhibitoru HIV-integrázy
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005112930A1 (en) * 2004-05-21 2005-12-01 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
SG170796A1 (en) * 2005-12-30 2011-05-30 Gilead Sciences Inc Us Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
TWI411613B (zh) * 2006-07-07 2013-10-11 Gilead Sciences Inc 用於改善被細胞色素p450單氧合酶所代謝之治療劑的藥物動力性質之調節劑
BRPI0716752A2 (pt) * 2006-09-12 2013-09-17 Gilead Sciences Inc processo e intermediÁrios para preparo de inibidores de intergrase
AR067183A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Composiciones terapeuticas y metodos, usos y equipos
KR20100028656A (ko) * 2007-06-29 2010-03-12 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
EA201591353A1 (ru) * 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
US20110000941A1 (en) * 2009-07-06 2011-01-06 Volk J Patrick Apparatus and System for Carrying a Digital Media Player

Also Published As

Publication number Publication date
US20170136001A1 (en) 2017-05-18
EA200971093A1 (ru) 2010-08-30
JP5769763B2 (ja) 2015-08-26
US20090093467A1 (en) 2009-04-09
SG182229A1 (en) 2012-07-30
WO2009006199A1 (en) 2009-01-08
CN103480000A (zh) 2014-01-01
JP2010532372A (ja) 2010-10-07
JP5547066B2 (ja) 2014-07-09
AU2008270630A1 (en) 2009-01-08
AP2009005074A0 (en) 2009-12-31
AP2965A (en) 2014-09-30
US20100331331A1 (en) 2010-12-30
ECSP109897A (es) 2010-03-31
CA2692101A1 (en) 2009-01-08
CN101686972A (zh) 2010-03-31
AU2008270630B2 (en) 2014-01-16
NZ582086A (en) 2012-07-27
CN101686972B (zh) 2013-08-14
BRPI0813000A2 (pt) 2014-12-23
JP2015143278A (ja) 2015-08-06
JP2013199495A (ja) 2013-10-03
CO6251237A2 (es) 2011-02-21
TW200914011A (en) 2009-04-01
KR20100040892A (ko) 2010-04-21
AR067183A1 (es) 2009-09-30
IL202744A0 (en) 2010-06-30
EP2167088A1 (en) 2010-03-31
US20140343063A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
MX2009013829A (es) Composiciones terapeuticas y su uso.
MX2009013828A (es) Composiciones terapeuticas y su uso.
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
MX2013012266A (es) Compuestos de benzotiazol y su uso farmaceutico.
SG178952A1 (en) Chemical compounds
MX2010002317A (es) Derivados de indol sustituidos y metodos para su utilizacion.
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
MX2010005356A (es) Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
MX2012015293A (es) Derivados de acido 2-quinolinil-acetico como compuestos antivirales.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
EA201170521A1 (ru) Новые соединения
WO2008127364A3 (en) Antiviral compounds and use thereof
GEP201706698B (en) Inhibitors of influenza viruses replication
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
TW200738725A (en) Unsaturated mTOR inhibitors
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
AU2012209283A8 (en) Process for the preparation of 4-amino-5-fluoro-3-halo-6-(substituted)picolinates
MX2012007076A (es) Terapia combinada de hcv.
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
IN2009KN03959A (es)
HK1102702A1 (en) Anti-viral uses of borinic acid complexes
MX2009008779A (es) Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación.